ZyVersa Therapeutics Inc.

NASDAQ ZVSA
$0.14 - -%
Today share price
USA
Sector: Healthcare Industry: Biotechnology
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Rating Finrange

Index: 10 %
Market cap Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.
1.95M
EV Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
-1.61B
Beta Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
-
Shares Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
3.11M
YTD Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
-

Upcoming events ZyVersa Therapeutics Inc.

All events
No upcoming events scheduled

Stock chart ZyVersa Therapeutics Inc.

Stock analysis ZyVersa Therapeutics Inc.

Indicator Company Industry
P/E (LTM) Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.
- -1.30
P/BV (LTM) Shows the ratio of the market price of the share to the current book value.
- 1.15
EV/EBITDA (LTM) Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.
0.35 -0.75
Net Debt/EBITDA (LTM) A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.
0.36 0.42
ROE (LTM) Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.
-57.35 -50.00

Price change ZyVersa Therapeutics Inc. per year

0.12$ 2.70$
Min Max

Summary analysis ZyVersa Therapeutics Inc.

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure ZyVersa Therapeutics Inc.

Revenue and net income ZyVersa Therapeutics Inc.

All parameters

About company ZyVersa Therapeutics Inc.

ZyVersa Therapeutics, Inc. operates as a clinical stage biopharmaceutical company that develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity. ZyVersa Therapeutics, Inc. was founded in 2014 and is based in Weston, Florida.
Address:
2200 N. Commerce Parkway, Weston, FL, United States, 33326
Company name: ZyVersa Therapeutics Inc.
Issuer ticker: ZVSA
ISIN: US98987D3008
Country: USA
Exchange: NASDAQ
Currency: $
IPO date: 2022-12-12
Sector: Healthcare
Industry: Biotechnology
Site: https://www.zyversa.com